Baker Avenue Asset Management LP Invests $707,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Baker Avenue Asset Management LP acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, HoldingsChannel reports. The fund acquired 673 shares of the biopharmaceutical company’s stock, valued at approximately $707,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of REGN. SteelPeak Wealth LLC raised its position in shares of Regeneron Pharmaceuticals by 173.0% during the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 692 shares during the period. Atria Investments Inc increased its position in Regeneron Pharmaceuticals by 12.2% in the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after buying an additional 941 shares during the period. Tri Locum Partners LP lifted its stake in Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after buying an additional 8,949 shares during the last quarter. Tidal Investments LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 16.8% during the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after acquiring an additional 711 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth about $1,232,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on REGN shares. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Royal Bank of Canada lowered their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. JPMorgan Chase & Co. reduced their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Piper Sandler cut their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,107.25.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $825.68 on Tuesday. The company has a market capitalization of $90.73 billion, a PE ratio of 20.43, a PEG ratio of 3.13 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company’s 50 day moving average price is $1,021.70 and its 200 day moving average price is $1,038.20. Regeneron Pharmaceuticals, Inc. has a 52 week low of $784.96 and a 52 week high of $1,211.20.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.